Abstract
Introduction: Immune checkpoint inhibitors (ICI) are the new standard therapy in patients with metastatic NSCLC (mNSCLC). Metformin, previously associated with improved chemotherapy efficacy in diabetic and nondiabetic cancer patients, was recently associated with increased ICI efficacy. In this study, we aimed to explore the correlations between diabetes mellitus (DM), metformin use, and benefit from ICI in mNSCLC patients. Methods: All mNSCLC patients treated with ICI in our center between February 2015 and April 2018 were identified. Demographic and clinical data were extracted retrospectively. Cox proportional hazards regression, t tests, and χ2 tests were employed to evaluate associations of progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and disease control rate (DCR), with DM status, metformin use, and HbA1c levels, as appropriate. Results: Of 249 mNSCLC patients treated with ICI, 57 (22.8%) had DM. Thirty-seven (64.9% of all diabetic patients) patients were treated with metformin. A significant negative correlation of DM with PFS and OS was demonstrated (HR 1.5 [1.01–2.06], p = 0.011, and HR 1.5 [1.08–2.08], p = 0.017, respectively). Metformin exposure had no significant correlation with PFS or OS in diabetic mNSCLC patients (HR 1.08 [0.61–1.93], p = 0.79, and HR 1.29 [0.69–2.39], p = 0.42, respectively). There were no differences between groups with respect to ORR and DCR. Conclusion: Our data show a potential negative relationship between DM and ICI efficacy in mNSCLC patients. In contrast to reports with chemotherapy, we found no positive relationship between metformin use and ICI therapy in diabetic patients with mNSCLC. Further studies are needed to evaluate the effect of metformin in nondiabetic mNSCLC patients.
References
1.
Garon
EB
, Hellmann
MD
, Rizvi
NA
, Carcereny
E
, Leighl
NB
, Ahn
M-J
, Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
. J Clin Oncol
. 2019 Oct 1
;37
(28
):2518
–27
.2.
Kepp
O
, Marabelle
A
, Zitvogel
L
, Kroemer
G
. Oncolysis without viruses: inducing systemic anticancer immune responses with local therapies
. Nat Rev Clin Oncol
. 2019 Oct 8
.3.
Havel
JJ
, Chowell
D
, Chan
TA
. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
. Nat Rev Cancer
. 2019
;19
:133
–50
. .4.
Sivan
A
, Corrales
L
, Hubert
N
, Williams
JB
, Aquino-Michaels
K
, Earley
ZM
, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
. Science
. 2015
[cited 2019 Nov 14];350
(6264
):1084
–9
.5.
Stumvoll
M
, Nurjhan
N
, Perriello
G
, Dailey
G
, Gerich
JE
. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
. N Engl J Med
. 1995 Aug 31
;333
(9
):550
–4
. .6.
Maniar
K
, Moideen
A
, Mittal
A
, Patil
A
, Chakrabarti
A
, Banerjee
D
. A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: genesis of a wonder drug?
Pharmacol Res
. 2017
[cited 2019 Nov 14];117
:103
–28
. .7.
Romero
R
, Erez
O
, Hüttemann
M
, Maymon
E
, Panaitescu
B
, Conde-Agudelo
A
, Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity
. Am J Obstet Gynecol
. 2017
;217
:282
–302
. .8.
Gandini
S
, Puntoni
M
, Heckman-Stoddard
BM
, Dunn
BK
, Ford
L
, DeCensi
A
, Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders
. Cancer Prev Res
. 2014
;7
:867
–85
. .9.
Daugan
M
, Dufaÿ Wojcicki
A
, d’Hayer
B
, Boudy
V
. Metformin: an anti-diabetic drug to fight cancer
. Pharmacol Res
. 2016
;113
:675
–85
. .10.
Marrone
KA
, Zhou
X
, Forde
PM
, Purtell
M
, Brahmer
JR
, Hann
CL
, A randomized phase II study of metformin plus paclitaxel/carboplatin/bevacizumab in patients with chemotherapy-naïve advanced or metastatic nonsquamous non-small cell lung cancer
. Oncologist
. 2018
[cited 2019 Nov 14];23
(7
):859
–65
. 11.
Cao
X
, Wen
ZS
, Wang
XD
, Li
Y
, Liu
KY
, Wang
X
. The clinical effect of metformin on the survival of lung cancer patients with diabetes: a comprehensive systematic review and meta-analysis of retrospective studies
. J Cancer
. 2017
;8
(13
):2532
–41
. .12.
Kumar
S
, Meuter
A
, Thapa
P
, Langstraat
C
, Giri
S
, Chien
J
, Metformin intake is associated with better survival in ovarian cancer: a case-control study
. Cancer
. 2013 Feb 1
[cited 2019 Nov 14];119
(3
):555
–62
. .13.
Ko
EM
, Walter
P
, Jackson
A
, Clark
L
, Franasiak
J
, Bolac
C
, Metformin is associated with improved survival in endometrial cancer
. Gynecol Oncol
. 2014 Feb
;132
(2
):438
–42
. .14.
Jiralerspong
S
, Palla
SL
, Giordano
SH
, Meric-Bernstam
F
, Liedtke
C
, Barnett
CM
, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer
. J Clin Oncol
. 2009 Jul 10
[cited 2019 Nov 14];27
(20
):3297
–302
. .15.
Arrieta
O
, Barrón
F
, Padilla
M-ÁS
, Avilés-Salas
A
, Ramírez-Tirado
LA
, Arguelles Jiménez
MJ
, Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial
. JAMA Oncol
. 2019 Sep 5
[cited 2019 Nov 14];5
:e192553
. .16.
Quinn
BJ
, Kitagawa
H
, Memmott
RM
, Gills
JJ
, Dennis
PA
. Repositioning metformin for cancer prevention and treatment
. Trends Endocrinol Metab
. 2013
;24
:469
–80
. .17.
Eikawa
S
, Nishida
M
, Mizukami
S
, Yamazaki
C
, Nakayama
E
, Udono
H
. Immune-mediated antitumor effect by type 2 diabetes drug, metformin
. Proc Natl Acad Sci U S A
. 2015 Feb 10
[cited 2019 Nov 14];112
(6
):1809
–14
. .18.
Kim
SH
, Li
M
, Trousil
S
, Zhang
Y
, Pasca di Magliano
M
, Swanson
KD
, Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma
. J Invest Dermatol
. 2017
[cited 2019 Nov 14];137
(8
):1740
–8
. .19.
Scharping
NE
, Menk
AV
, Whetstone
RD
, Zeng
X
, Delgoffe
GM
. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia
. Cancer Immunol Res
. 2017
[cited 2019 Nov 14];5
(1
):9
–16
. .20.
Wang
JC
, Sun
X
, Ma
Q
, Fu
GF
, Cong
LL
, Zhang
H
, Metformin’s antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization
. J Cell Mol Med
. 2018 Aug 1
;22
(8
):3825
–36
. .21.
Wu
H
, Esteve
E
, Tremaroli
V
, Khan
MT
, Caesar
R
, Mannerås-Holm
L
, Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
. Nat Med
. 2017 Jul 1
;23
(7
):850
–8
. .22.
Matson
V
, Fessler
J
, Bao
R
, Chongsuwat
T
, Zha
Y
, Alegre
ML
, The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
. Science
. 2018
[cited 2019 Nov 14];359
(6371
):104
–8
. .23.
Geerlings
SE
, Hoepelman
AIM
. Immune dysfunction in patients with diabetes mellitus (DM)
. FEMS Immunol Med Microbiol
. 1999
[cited 2019 Nov 30];26
(3–4
):259
–65
. .24.
Delamaire
M
, Maugendre
D
, Moreno
M
, Le Goff
MC
, Allannic
H
, Genetet
B
. Impaired leucocyte functions in diabetic patients
. Diabet Med
. 1997
;14
(1
):29
–34
. .25.
Mazade
MA
, Edwards
MS
. Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes
. Mol Genet Metab
. 2001
;73
(3
):259
–67
. .26.
Zykova
SN
, Jenssen
TG
, Berdal
M
, Olsen
R
, Myklebust
R
, Seljelid
R
. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice
. Diabetes
. 2000
;49
(9
):1451
–8
. .27.
Price
CL
, Hassi
HOSA
, English
NR
, Blakemore
AIF
, Stagg
AJ
, Knight
SC
. Methylglyoxal modulates immune responses: relevance to diabetes
. J Cell Mol Med
. 2010 Jun
;14
(6B
):1806
–15
. .28.
Huang
CY
, Ju
DT
, Chang
CF
, Muralidhar Reddy
P
, Velmurugan
BK
. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer
. Biomedicine
. 2017
;7
:23
. .29.
Granier
C
, De Guillebon
E
, Blanc
C
, Roussel
H
, Badoual
C
, Colin
E
, Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
. ESMO Open
. 2017
;2
:e000213
.30.
Strulov Shachar
S
, Fried
R
, Shafran
I
, Moskovitz
MT
, Williams
GR
, Bar-Sela
G
, Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo)
. J Clin Oncol
. 2018 May 20
;36
(15 Suppl
):e21010
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
